Age <65 years N=1122 %/mean±SD | Age 65–74 N=771 %/mean±SD | Age ≥75 N=569 %/mean±SD | P value (<65 vs 65–74 vs ≥75) | |
Age (years) | 55.5±7.7 | 69.7±3.0 | 79.3±3.9 | <0.0001 |
Women* | 41.0 | 48.4 | 56.0 | <0.0001 |
Body weight (kg) | 95.1±18.6 | 88.7±15.8 | 82.4±15.2 | <0.0001 |
Body mass index (kg/m²) | 32.0±5.6 | 31.0±5.2 | 29.7±5.0 | <0.0001 |
Diabetes duration (years) | 6.8±5.4 | 8.9±6.1 | 11.2±7.2 | <0.0001 |
Baseline FBG (mg/dL) | 186.5±41.2 | 180.1±39.0 | 181.1±40.5 | 0.0019 |
Baseline HbA1c (%/mmol/mol) | 8.6±0.8/70±9 | 8.4±0.8/68±9 | 8.5±0.8/69±9 | <0.0001 |
Individual target HbA1c (%/mmol/mol) | 6.8±0.5/51±5 | 6.9±0.4/52±4 | 7.1±0.5/54±5 | <0.0001 |
Diabetes therapy at baseline | ||||
OADs | ||||
Metformin† | 63.2 | 59.7 | 53.3 | 0.0004 |
DPP-4i‡ | 23.7 | 28.3 | 31.8 | 0.0012 |
Sulfonylurea† | 13.2 | 18.7 | 22.7 | <0.0001 |
Glinide | 5.4 | 5.2 | 9.5 | 0.0013 |
Glitazone† | 2.2 | 1.0 | 0.9 | 0.0499 |
GLP-1 RA† | 2.1 | 0.8 | 0.4 | 0.0028 |
SGLT-2 inhibitor† | 3.6 | 3.4 | 1.6 | 0.0516 |
Acarbose | 0.6 | 0.9 | 1.1 | 0.5689 |
Others† | 0.4 | 0.3 | 0.0 | 0.2923 |
Insulin | ||||
Basal insulin (any) | 8.3 | 9.1 | 9.1 | 0.7744 |
NPH insulin | 4.9 | 5.5 | 5.3 | 0.8528 |
Insulin detemir | 2.0 | 2.3 | 1.8 | 0.7662 |
Insulin glargine | 0.6 | 0.7 | 0.7 | 1.000 |
Short-acting analogues | 0.2 | 0.3 | 0.5 | 0.4912 |
Premixed insulins | 0.5 | 0.4 | 0.9 | 0.5060 |
Other insulins | 0.4 | 0.1 | 0.0 | 0.4524 |
Diabetes therapy at 12 months | ||||
OADs | ||||
Metformin† | 53.1 | 50.3 | 44.1 | 0.0022 |
DPP-4i‡ | 20.5 | 24.0 | 25.0 | 0.0643 |
Sulfonylurea† | 6.4 | 13.0 | 15.6 | <0.0001 |
Glinide | 4.5 | 4.0 | 7.2 | 0.0224 |
Glitazone† | 2.0 | 1.0 | 0.7 | 0.0811 |
GLP-1 RA† | 1.5 | 0.9 | 0.5 | 0.1680 |
SGLT-2 inhibitor† | 6.3 | 3.9 | 1.8 | <0.0001 |
Acarbose | 0.4 | 0.5 | 0.5 | 0.7925 |
Others† | 0.8 | 0.5 | 0.5 | 0.7660 |
Insulin | ||||
Continuation of Gla-100 | 87.3 | 85.3 | 83.7 | 0.1204 |
Change to other basal insulin | 0.3 | 0.7 | 0.4 | 0.5042 |
Change insulin type | 2.0 | 2.5 | 3.9 | 0.0688 |
Not stated | 10.8 | 12.1 | 12.3 | 0.5605 |
*17 patients missing this information (<65: 6 patients; 65–74: 8 patients; ≥75: 3 patients). Values are stated as percentages or mean±SD.
†Alone or in combination with any other OAD(s).
‡Alone or in combination with any other OAD(s) except metformin.
DPP-4i, dipeptidyl peptidase-4 inhibitor; FBG, capillary fasting blood glucose; GLP-1 RA, glucagon-like peptide-1 receptor agonist; NPH, neutral protamine Hagedorn; OAD, oral antidiabetic therapy; SGLT-2, sodium-glucose cotransporter-2.